Altimmune heads into a pivotal 2026 MASH race, betting its dual agonist pemvidutide can stand out in a crowded field as key catalysts and risks...

Viking Therapeutics climbs after it completes enrollment in the second phase III obesity study for VK2735 and advances its bid in a fast-growing,...

Bayer advances AB-1002 after AskBio completes mid-stage study enrollment, as its Pharma strategy and pipeline milestones drive long-term growth...

A study published in Cell Research advances a central idea in stem cell biology by identifying a checkpoint that controls the identity of many...

Altimmune heads into 2026 with high-stakes catalysts as pemvidutide drives its pipeline, but funding needs and dilution risk loom alongside key...

AstraZeneca jumps as tozorakimab hits primary goals in two phase III COPD trials, cuts exacerbations and shows promise in a disease with limited...

TUESDAY, March 31, 2026 -- For adults with type 2 diabetes, discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated...

TUESDAY, March 31, 2026 -- For adults with type 2 diabetes, discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated...

THURSDAY, April 2, 2026 -- Glucagon-like peptide-1 (GLP-1) receptor agonist (RA) use is associated with delayed wound healing in patients undergoing...

THURSDAY, April 2, 2026 -- Glucagon-like peptide-1 (GLP-1) receptor agonist (RA) use is associated with delayed wound healing in patients undergoing...